{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T04:45:18Z","timestamp":1792125918472,"version":"4.4.0"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T00:00:00Z","timestamp":1790985600000},"content-version":"vor","delay-in-days":2,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.euo.2026.10.002","type":"journal-article","created":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T03:56:29Z","timestamp":1792122989000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prostate Cancer Incidence and Disease Characteristics in Transgender Women Receiving Gender-affirming Hormone Therapy: A Systematic Review with Meta-analysis"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-6621-1027","authenticated-orcid":false,"given":"Kunind","family":"Oberoi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella","family":"Trevaskis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadia","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kapil","family":"Sethi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2026.10.002_b0005","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.eururo.2023.04.021","article-title":"2022 Update on prostate cancer epidemiology and risk factors\u2014a systematic review","volume":"84","author":"Bergengren","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.10.002_b0010","doi-asserted-by":"crossref","first-page":"e3293","DOI":"10.1210\/clinem\/dgaa412","article-title":"Prostate cancer incidence under androgen deprivation: nationwide cohort study in trans women receiving hormone treatment","volume":"105","author":"de Nie","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.euo.2026.10.002_b0015","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1001\/jamaoncol.2024.4335","article-title":"Prevalence and factors associated with prostate cancer among transgender women","volume":"10","author":"Manfredi","year":"2024","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.euo.2026.10.002_b0020","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/s41391-024-00804-4","article-title":"Incidence of prostate cancer in transgender women in the US: a large database analysis","volume":"28","author":"Loria","year":"2025","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.euo.2026.10.002_b0025","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1001\/jama.2023.6028","article-title":"Prostate cancer in transgender women in the Veterans Affairs health system, 2000\u20132022","volume":"329","author":"Nik-Ahd","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.euo.2026.10.002_b0030","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1080\/26895269.2025.2503225","article-title":"Prostatic diseases in transgender women: a systematic review of diagnosis, risk, and management","volume":"27","author":"Bourillon","year":"2026","journal-title":"Int J Transgend Health"},{"key":"10.1016\/j.euo.2026.10.002_b0035","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/bju.15521","article-title":"Prostate cancer in transgender women: what does a urologist need to know?","volume":"129","author":"Bertoncelli Tanaka","year":"2022","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2026.10.002_b0040","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.urology.2017.08.032","article-title":"Prostate cancer in transgender women: incidence, etiopathogenesis, and management challenges","volume":"110","author":"Deebel","year":"2017","journal-title":"Urology"},{"key":"10.1016\/j.euo.2026.10.002_b0045","first-page":"2127","article-title":"Methodological quality of case series studies: an introduction to the JBI critical appraisal tool","volume":"18","author":"Munn","year":"2020","journal-title":"JBI Evid Synth"},{"key":"10.1016\/j.euo.2026.10.002_b0050","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.euo.2026.10.002_b0055","article-title":"Introduction to the GRADE tool for rating certainty in evidence and recommendations","volume":"25","author":"Prasad","year":"2024","journal-title":"Clin Epidemiol Glob Health"},{"key":"10.1016\/j.euo.2026.10.002_b0060","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.urology.2025.07.055","article-title":"Prostate specific antigen testing and prostate cancer diagnosis rates among transgender and non-binary patients: retrospective review of a single-institution experience","volume":"206","author":"Michael","year":"2025","journal-title":"Urology"},{"key":"10.1016\/j.euo.2026.10.002_b0065","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.ijrobp.2024.09.039","article-title":"Prostate-specific antigen and prostate cancer in gender-affirming hormone therapy for transgender or nonbinary individuals","volume":"121","author":"Morgan","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.euo.2026.10.002_b0070","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1097\/PAS.0000000000001964","article-title":"Prostate cancer in male-to-female transgender individuals: histopathologic findings and association with gender-affirming hormonal therapy","volume":"46","author":"Baraban","year":"2022","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.euo.2026.10.002_b0075","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1080\/26895269.2025.2551143","article-title":"Assessment of breast and prostate cancer risk in trans and gender diverse individuals receiving gender-affirming hormone therapy","volume":"27","author":"Wang","year":"2026","journal-title":"Int J Transgend Health"},{"key":"10.1016\/j.euo.2026.10.002_b0080","doi-asserted-by":"crossref","first-page":"3863","DOI":"10.1002\/cncr.35469","article-title":"Prostate cancer in transgender women: Aa propensity score-matched analysis of disease severity and survival","volume":"130","author":"Meagher","year":"2024","journal-title":"Cancer"},{"key":"10.1016\/j.euo.2026.10.002_b0085","first-page":"485","article-title":"Prostate cancer statistics, 2025","volume":"75","author":"Kratzer","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.euo.2026.10.002_b0090","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/cam4.549","article-title":"Recent decline in prostate cancer incidence in the United States, by age, stage, and Gleason score","volume":"5","author":"Herget","year":"2016","journal-title":"Cancer Med"},{"key":"10.1016\/j.euo.2026.10.002_b0095","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.eururo.2008.09.024","article-title":"Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth","volume":"55","author":"Morgentaler","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.10.002_b0100","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41391-024-00796-1","article-title":"Gender-affirming hormone therapy in transgender women and risk of prostate cancer: pathophysiological mechanisms and clinical implications","volume":"28","author":"Bologna","year":"2025","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.euo.2026.10.002_b0105","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1002\/ijc.29538","article-title":"Prevalence of incidental prostate cancer: a systematic review of autopsy studies","volume":"137","author":"Bell","year":"2015","journal-title":"Int J Cancer"},{"key":"10.1016\/j.euo.2026.10.002_b0110","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/S0140-6736(16)00684-X","article-title":"Global health burden and needs of transgender populations: a review","volume":"388","author":"Reisner","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.euo.2026.10.002_b0115","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.2105\/AJPH.2012.300796","article-title":"Experiences of transgender-related discrimination and implications for health: results from the Virginia transgender health initiative study","volume":"103","author":"Bradford","year":"2013","journal-title":"Am J Public Health"},{"issue":"Suppl_3","key":"10.1016\/j.euo.2026.10.002_b0120","doi-asserted-by":"crossref","first-page":"S263","DOI":"10.21037\/tau.2019.03.13","article-title":"Can the interplay between androgen signaling and PSMA expression be leveraged for theranostic applications?","volume":"8","author":"Batra","year":"2019","journal-title":"Transl Androl Urol"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931126002762?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931126002762?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T03:56:32Z","timestamp":1792122992000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931126002762"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":24,"alternative-id":["S2588931126002762"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2026.10.002","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prostate Cancer Incidence and Disease Characteristics in Transgender Women Receiving Gender-affirming Hormone Therapy: A Systematic Review with Meta-analysis","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2026.10.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}